Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Hummingbird Bioscience

Precision Medicine. Precision Therapies.

## Sitemaps

- [XML Sitemap](https://hummingbirdbioscience.com/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Hummingbird Bioscience Wins APAC Trailblazer Award at 2026 Nebius AI Discovery Awards](https://hummingbirdbioscience.com/hummingbird-bioscience-wins-apac-trailblazer-award-at-2026-nebius-ai-discovery-awards/) - Hummingbird Bioscience has won the Asia Pacific Trailblazer Award at the 2026 AI Discovery Awards hosted by Nebius.
- [Hummingbird Bioscience Closes US$25 Million Investment With Series B Extension](https://hummingbirdbioscience.com/hummingbird-bioscience-closes-us25-million-investment-with-series-b-extension/) - Hummingbird Bioscience, an innovative biotherapeutics company focused on the discovery and development of new breakthrough therapies, has closed an extended Series B funding round of US$25 million.
- [Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-first-patient-dosed-in-phase-i-clinical-trial-of-hmbd-501-in-advanced-her3-expressing-solid-malignancies/) - Hummingbird Bioscience today announced that the first patient has been dosed in a Phase I clinical trial of HMBD-501 for the treatment of patients with advanced HER3-expressing solid malignancies
- [Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics](https://hummingbirdbioscience.com/hummingbird-bioscience-licenses-hmbd-002-phase-ii-ready-anti-vista-monoclonal-antibody-to-percheron-therapeutics/) - Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s HMBD-002 for further clinical development. Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics.
- [Hummingbird Bioscience Appoints Dipti Thakkar, PhD, as Chief Operating Officer](https://hummingbirdbioscience.com/hummingbird-bioscience-appoints-dipti-thakkar-phd-as-chief-operating-officer/) - Hummingbird Bioscience today announced the internal appointment of Dipti Thakkar, PhD, as Chief Operating Officer.
- [Hummingbird Bioscience Awarded $13.1 Million Grant by the Cancer Prevention and Research Institute of Texas (CPRIT)](https://hummingbirdbioscience.com/hummingbird-bioscience-awarded-13-1-million-grant-by-the-cancer-prevention-and-research-institute-of-texas-cprit/)
- [Hummingbird Bioscience Announces Collaboration with Tempus to Harness AI-Driven Precision Medicine to Accelerate Clinical Development of HMBD-001 in HER3-Driven Cancers Including NRG1 Fusions](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-collaboration-with-tempus-to-harness-ai-driven-precision-medicine-to-accelerate-clinical-development-of-hmbd-001-in-her3-driven-cancers-including-nrg1-fusions/)
- [Hummingbird Bioscience Presents Pre-Clinical Data on its Next-Generation BCMA-TACI Dual-Specific T Cell Engager at 2021 AACR Annual Meeting](https://hummingbirdbioscience.com/hummingbird-bioscience-presents-pre-clinical-data-on-its-next-generation-bcma-taci-dual-specific-t-cell-engager-at-2021-aacr-annual-meeting/)
- [Hummingbird Bioscience Raises US$125 Million in Series C Financing](https://hummingbirdbioscience.com/hummingbird-bioscience-raises-us125-million-in-series-c-financing/)
- [Hummingbird Bioscience Announces Publication of Abstract on Anti-VISTA Antibody HMBD-002 at the American Society Of Clinical Oncology (ASCO) 2021 Annual Meeting](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-publication-of-abstract-on-anti-vista-antibody-hmbd-002-at-the-american-society-of-clinical-oncology-asco-2021-annual-meeting/)
- [Hummingbird Bioscience and Novogene Enter into Strategic Partnership to Expand Precision Medicine Testing for Individuals with NRG1 Fusion-Driven Cancers in China](https://hummingbirdbioscience.com/hummingbird-bioscience-and-novogene-enter-into-strategic-partnership-to-expand-precision-medicine-testing-for-individuals-with-nrg1-fusion-driven-cancers-in-china/)
- [Hummingbird Bioscience to Speak at 2021 Virtual Symposium: “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond”](https://hummingbirdbioscience.com/hummingbird-bioscience-to-speak-at-2021-virtual-symposium-vista-a-new-immune-checkpoint-in-cancer-autoimmunity-and-beyond/)
- [Hummingbird Bioscience Appoints Renowned Scientist and Medical Oncologist Dr. Thomas J. Lynch to its Board of Directors](https://hummingbirdbioscience.com/hummingbird-bioscience-appoints-renowned-scientist-and-medical-oncologist-dr-thomas-j-lynch-to-its-board-of-directors/)
- [View Replay: 3rd Annual Virtual VISTA Symposium](https://hummingbirdbioscience.com/view-replay-3rd-annual-virtual-vista-symposium/) - Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
- [Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept](https://hummingbirdbioscience.com/callio-therapeutics-launches-with-us187-million-series-a-to-advance-multi-payload-antibody-drug-conjugate-platform-through-clinical-proof-of-concept/) - Callio Therapeutics today announced its launch with the closing of a $187.0 million Series A financing round.
- [Hummingbird Bioscience Licenses Novel Antibodies to Immunome](https://hummingbirdbioscience.com/hummingbird-bioscience-licenses-novel-antibodies-to-immunome/) - Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, an exclusive, worldwide license to monoclonal antibodies that are directed to a single undisclosed target.
- [Cancer Research, Volume 77, Issue 13, AACR Journals: HMBD-002, a novel neutralizing antibody targeting a specific epitope on the co-inhibitory immune checkpoint receptor VISTA, displays potent anti-tumor effects in pre-clinical models](https://hummingbirdbioscience.com/cancer-research-volume-77-issue-13-aacr-journals-hmbd-002-a-novel-neutralizing-antibody-targeting-a-specific-epitope-on-the-co-inhibitory-immune-checkpoint-receptor-vista-displays-potent-anti-tu/)
- [Cancer Research, Volume 77, Issue 13 Supplement, AACR Journals: HMBD-001, a novel anti-ErbB3 antibody with a unique mechanism of action, effectively inhibits tumor growth in pre-clinical models of ErbB3+ solid tumors](https://hummingbirdbioscience.com/cancer-research-volume-77-issue-13-supplement-aacr-journals-hmbd-001-a-novel-anti-erbb3-antibody-with-a-unique-mechanism-of-action-effectively-inhibits-tumor-growth-in-pre-clinical-models-of-erb/)
- [Cancer Research, Volume 78, Issue 13, Supplement, AACR Journals: Integrative immune profiling of syngeneic tumor models provides predictive immune signatures for treatment response with HMBD-002, a novel anti-VISTA neutralizing antibody](https://hummingbirdbioscience.com/cancer-research-volume-78-issue-13-supplement-aacr-journals-integrative-immune-profiling-of-syngeneic-tumor-models-provides-predictive-immune-signatures-for-treatment-response-with-hmbd-002-a-no/)
- [European Journal of Cancer: A novel humanized anti-HER3 antibody with a unique mechanism of action, demonstrates superior tumor inhibition in multiple tumor models compared to other EGFR family therapies.](https://hummingbirdbioscience.com/european-journal-of-cancer-a-novel-humanized-anti-her3-antibody-with-a-unique-mechanism-of-action-demonstrates-superior-tumor-inhibition-in-multiple-tumor-models-compared-to-other-egfr-family-therap/)
- [Journal for ImmunoTherapy of Cancer: P477 HMBD-002-V4: A novel anti-VISTA antibody that uniquely binds murine and human VISTA and potently inhibits tumor growth by remodeling the immunosuppressive tumor microenvironment](https://hummingbirdbioscience.com/journal-for-immunotherapy-of-cancer-p477-hmbd-002-v4-a-novel-anti-vista-antibody-that-uniquely-binds-murine-and-human-vista-and-potently-inhibits-tumor-growth-by-remodeling-the-immunosuppressive-tum/)
- [Molecular Cancer Therapeutics, AACR Journals: 10D1F, an anti-HER3 antibody that uniquely blocks the receptor heterodimerization interface, potently inhibits tumor growth across a broad panel of tumor models](https://hummingbirdbioscience.com/molecular-cancer-therapeutics-aacr-journals-10d1f-an-anti-her3-antibody-that-uniquely-blocks-the-receptor-heterodimerization-interface-potently-inhibits-tumor-growth-across-a-broad-panel-of-tumor/)
- [AACR-NCI-EORTC Virtual International Conference 2021: An anti-HER3 antibody, HMBD-001, that uniquely binds to and blocks the HER3 heterodimerization interface, shows superior tumor growth inhibition in biomarker-defined preclinical cancer models including NRG1 fusion driven cancers](https://hummingbirdbioscience.com/aacr-nci-eortc-virtual-international-conference-2021-an-anti-her3-antibody-hmbd-001-that-uniquely-binds-to-and-blocks-the-her3-heterodimerization-interface-shows-superior-tumor-growth-inhibition-i/)
- [SITC 2021: A Phase 1 First-in-Human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies](https://hummingbirdbioscience.com/sitc-2021-a-phase-1-first-in-human-study-of-hmbd-002-an-igg4-monoclonal-antibody-targeting-vista-as-a-monotherapy-and-combined-with-pembrolizumab-in-patients-with-advanced-solid-malignancies/)
- [Journal for ImmunoTherapy of Cancer: Rationally targeted anti-VISTA antibody that blockades the C-C’ loop region can reverse VISTA immune suppression and remodel the immune microenvironment to potently inhibit tumor growth in an Fc independent manner.](https://hummingbirdbioscience.com/journal-for-immunotherapy-of-cancer-rationally-targeted-anti-vista-antibody-that-blockades-the-c-c-loop-region-can-reverse-vista-immune-suppression-and-remodel-the-immune-microenvironment-to/)
- [SITC 2022: Trial in Progress: A phase 1 first-in-human study of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies](https://hummingbirdbioscience.com/sitc-2022-trial-in-progress-a-phase-1-first-in-human-study-of-hmbd-002-an-igg4-monoclonal-antibody-targeting-vista-as-a-monotherapy-and-combined-with-pembrolizumab-in-patients-with-advanced-solid/)
- [SITC 2022: Anti-VISTA antibody HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T cell response](https://hummingbirdbioscience.com/sitc-2022-anti-vista-antibody-hmbd-002-reprograms-tumor-associated-macrophages-and-promotes-cytotoxic-t-cell-response/)
- [AACR 2023: HMBD-501 – a novel Fc engineered, exatecan-based next-generation HER3-targeting Antibody-Drug Conjugate (ADC) shows robust tolerability and efficacy in pre-clinical solid tumor models](https://hummingbirdbioscience.com/hmbd-501-a-novel-fc-engineered-exatecan-based-next-generation-her3-targeting-antibody-drug-conjugate-adc-shows-robust-tolerability-and-efficacy-in-pre-clinical-solid-tumor-models/) - We have developed HMBD-501, a novel anti-HER3 ADC with (i) a high-affinity Fab, which can bind to HER3 in the presence or absence of its ligand NRG1, (ii) an engineered Fc-domain to avoid FcgR binding and potential toxicities, and (iii) site-specific conjugation to a next generation cleavable linker and exatecan-based payload.
- [AACR 2023: Anti-HER3 antibody, HMBD-001, in combination with an EGFR inhibitor effectively inhibits tumor growth in biomarker selected pre-clinical models of squamous cell carcinomas](https://hummingbirdbioscience.com/anti-her3-antibody-hmbd-001-in-combination-with-an-egfr-inhibitor-effectively-inhibits-tumor-growth-in-biomarker-selected-pre-clinical-models-of-squamous-cell-carcinomas/) - The poster for HMBD-001 highlights that inhibition of HER3 has broad applicability in squamous cell carcinomas and this anti-tumor activity can be enhanced with concurrent inhibition of EGFR, with significant potential to improve patient outcomes. Robust tumor growth inhibition in various preclinical squamous cancer models, including lung, esophageal and head and neck, is observed with HMBD-001 when used as monotherapy and in combination with cetuximab.
- [AAI Immunology 2023: Targeting pathogenic auto-reactive VH4-34 B cells with a rationally developed and highly specific anti-VH4-34 antibody offers a new therapeutic approach for VH4-34 autoimmune disorders](https://hummingbirdbioscience.com/hmbd-011-targeting-pathogenic-auto-reactive-vh4-34-b-cells-with-a-rationally-developed-and-highly-specific-anti-vh4-34-antibody-offers-a-new-therapeutic-approach-for-vh4-34-autoimmune-disorders/)
- [ASCO 2023: A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors](https://hummingbirdbioscience.com/hmbd-002-a-phase-1-first-in-human-clinical-trial-of-hmbd-002-an-igg4-monoclonal-antibody-targeting-vista-in-advanced-solid-tumors/)
- [ESMO 2023: A CRUK phase I/IIA, first in human dose‐escalation and expansion trial of HMBD‐001 (an anti‐HER3 antibody) in patients with advanced HER3 positive solid tumours](https://hummingbirdbioscience.com/a-cruk-phase-i-iia-first-in-human-dose‐escalation-and-expansion-trial-of-hmbd‐001-an-anti‐her3-antibody-in-patients-with-advanced-her3-positive-solid-tumours/) - HMBD-001 is Hummingbird Bioscience’s proprietary anti-HER3 antibody in Phase I/IIa trials in the UK and Phase Ib trials in Australia, targeting multiple solid tumors The clinical data shows that HMBD-001 is safe and well-tolerated with no dose-limiting toxicities and no severe treatment-related adverse events Disease control rate (DCR) was 43% (9/21), with one patient achieving a partial response after two cycles of HMBD-001 monotherapy and a best overall response of 51% tumor shrinkage
- [AACR 2024: A HER3 antibody that uniquely blocks the HER3 heterodimerization  interface effectively inhibits tumor growth in pre-clinical  models with potentially oncogenic HER3 mutations](https://hummingbirdbioscience.com/a-her3-antibody-that-uniquely-blocks-the-her3-heterodimerization-interface-effectively-inhibits-tumor-growth-in-pre-clinical-models-with-potentially-oncogenic-her3-mutations/)
- [AACR 2024: The VISTA blocking antibody HMBD-002 promotes type-I interferon signaling and drives anti-tumor responses through macrophage  reprograming and cytotoxic CD8+ T cell activation](https://hummingbirdbioscience.com/the-vista-blocking-antibody-hmbd-002-promotes-type-i-interferon-signaling-and-drives-anti-tumor-responses-through-macrophage-reprograming-and-cytotoxic-cd8-t-cell-activation/)
- [WCLC 2024: A Phase Ib Study to Evaluate HMBD‑001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD‑001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers](https://hummingbirdbioscience.com/wclc-2024-a-phase-ib-study-to-evaluate-hmbd‑001-in-combination-with-docetaxel-with-or-without-cetuximab-in-participants-with-advanced-squamous-non-small-cell-lung-cancers-and-hmbd‑00/)
- [Festival of Biologics 2024: The Hummingbird Abvantage™: Engineering immune responses for epitope-focused antibody discovery](https://hummingbirdbioscience.com/fob2024-the-hummingbird-abvantage/)
- [EORTC-NCI-AACR 2024: A novel HER2 targeted dual-payload ADC, HMBD‑802 overcomes resistance to topoisomerase 1 inhibitor ADCs](https://hummingbirdbioscience.com/eortc-nci-aacr-2024-a-novel-her2-targeted-dual-payload-adc-hmbd‑802-overcomes-resistance-to-topoisomerase-1-inhibitor-adcs/)
- [Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-poster-presentation-on-hmbd-802-novel-dual-payload-antibody-drug-conjugate-at-eortc-nci-aacr-2024/) - Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced a poster presentation on HMBD-802, a novel first-in-class dual-payload anti-HER2 antibody-drug conjugate, at the 36th EORTC-NCI-AACR symposium (23-25 October 2024).
- [WCLC 2023: Combining anti-HER3 antibody, HMBD-001, with EGFR inhibition and chemotherapy may improve treatment outcomes in squamous NSCLC](https://hummingbirdbioscience.com/combining-anti-her3-antibody-hmbd-001-with-egfr-inhibition-and-chemotherapy-may-improve-treatment-outcomes-in-squamous-nsclc/)
- [Hummingbird Bioscience Announces Key Leadership Appointments](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-key-leadership-appointments/) - Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced the internal appointments of Kon Yew Kwek, BM BCh, DPhil, and Lisa Ooi, PhD, as Chief Medical Officer and Chief Operating Officer, respectively.
- [Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024](https://hummingbirdbioscience.com/hummingbird-bioscience-presents-new-preclinical-data-highlighting-next-generation-antibody-drug-conjugate-capabilities-at-pegs-boston-2024/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced two upcoming presentations at PEGS Boston 2024 (13-17 May).
- [Hummingbird Bioscience, a rapidly growing therapeutic antibody discovery company today announced it has closed a venture funding round of an undisclosed amount from Decheng Capital](https://hummingbirdbioscience.com/hummingbird-bioscience-a-rapidly-growing-therapeutic-antibody-discovery-company-today-announced-it-has-closed-a-venture-funding-round-of-an-undisclosed-amount-from-decheng-capital/)
- [Hummingbird Bioscience to present data on HMBD-004A at the 59th American Society of Hematology (ASH) Annual Meeting](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-data-on-hmbd-004a-at-the-59th-american-society-of-hematology-ash-annual-meeting/)
- [Hummingbird Bioscience to present data on HMBD-002-V4 at the American Association for Cancer Research (AACR) 2018 Annual Meeting](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-data-on-hmbd-002-v4-at-the-american-association-for-cancer-research-aacr-2018-annual-meeting/)
- [Hummingbird Bioscience to present data on HMBD-002-V4 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-data-on-hmbd-002-v4-at-the-society-for-immunotherapy-of-cancer-sitc-33rd-annual-meeting/)
- [Hummingbird Bioscience to present poster data on HMBD-001-10D1 at the EORTC-NCI-AACR’s 30th Annual Meeting](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-poster-data-on-hmbd-001-10d1-at-the-eortc-nci-aacrs-30th-annual-meeting/)
- [Hummingbird Bioscience Announces Nobel Laureate Dr. James Allison and Dr. Padmanee Sharma Join its Scientific Advisory Board](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-nobel-laureate-dr-james-allison-and-dr-padmanee-sharma-join-its-scientific-advisory-board/)
- [Cancer Research UK and Hummingbird Bioscience Join Forces to Advance Novel Antibody Drug into Clinical Trials](https://hummingbirdbioscience.com/cancer-research-uk-and-hummingbird-bioscience-join-forces-to-advance-novel-antibody-drug-into-clinical-trials/)
- [Hummingbird Bioscience Announces Collaboration with Amgen to Co-Discover Novel Therapeutics Using Hummingbird’s Rational Antibody Discovery Platform](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-collaboration-with-amgen-to-co-discover-novel-therapeutics-using-hummingbirds-rational-antibody-discovery-platform/)
- [Hummingbird Bioscience raises $19 Million in Series B financing to support expansion of its discovery pipeline and rapid development of its portfolio of targeted antibody therapeutics](https://hummingbirdbioscience.com/hummingbird-bioscience-raises-19-million-in-series-b-financing-to-support-expansion-of-its-discovery-pipeline-and-rapid-development-of-its-portfolio-of-targeted-antibody-therapeutics/)
- [Hummingbird Bioscience and MD Anderson Announce Strategic Research Collaboration to Advance Innovative Immunotherapies](https://hummingbirdbioscience.com/hummingbird-bioscience-and-md-anderson-announce-strategic-research-collaboration-to-advance-innovative-immunotherapies/)
- [Hummingbird Bioscience Announces UK MHRA Approval for First-in-Human Phase 1 Trial of HMBD-001 in Advanced Cancers](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-uk-mhra-approval-for-first-in-human-phase-1-trial-of-hmbd-001-in-advanced-cancers/)
- [Hummingbird Bioscience Strengthens Leadership Team with Appointment of Josh House as Chief Financial Officer](https://hummingbirdbioscience.com/hummingbird-bioscience-strengthens-leadership-team-with-appointment-of-josh-house-as-chief-financial-officer/)
- [Hummingbird Bioscience Announces US FDA Clearance of IND for First-in-Human Phase 1 Trial of HMBD-002 in Patients with Advanced Solid Tumors](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-us-fda-clearance-of-ind-for-first-in-human-phase-1-trial-of-hmbd-002-in-patients-with-advanced-solid-tumors/)
- [Hummingbird Bioscience Opens New Office and Research Facilities](https://hummingbirdbioscience.com/hummingbird-bioscience-opens-new-office-and-research-facilities/)
- [Hummingbird Bioscience to Present Pre-Clinical Data on Novel Biomarkers for HER3-Driven Cancers](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-pre-clinical-data-on-novel-biomarkers-for-her3-driven-cancers/)
- [Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer](https://hummingbirdbioscience.com/hummingbird-bioscience-to-collaborate-with-merck-on-clinical-trial-of-anti-vista-antibody-hmbd-002-in-combination-with-keytruda-pembrolizumab-for-treatment-of-cancer/)
- [Hummingbird Bioscience Announces Trials in Progress Poster Presentation at the Society for Immunotherapy of Cancer 2021 36th Annual Meeting](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-trials-in-progress-poster-presentation-at-the-society-for-immunotherapy-of-cancer-2021-36th-annual-meeting/)
- [Hummingbird Bioscience Appoints Jan Møller Mikkelsen as Chairman of the Board](https://hummingbirdbioscience.com/hummingbird-bioscience-appoints-jan-moller-mikkelsen-as-chairman-of-the-board/)
- [Hummingbird Bioscience Announces First Patient Dosed in Phase 1 Clinical Trial of HMBD-001 in Advanced HER3-Expressing Solid Malignancies](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-first-patient-dosed-in-phase-1-clinical-trial-of-hmbd-001-in-advanced-her3-expressing-solid-malignancies/)
- [Hummingbird Bioscience Publishes Preclinical Data Demonstrating Therapeutic Potential of HMBD-002 in VISTA-expressing Cancers](https://hummingbirdbioscience.com/hummingbird-bioscience-publishes-preclinical-data-demonstrating-therapeutic-potential-of-hmbd-002-in-vista-expressing-cancers/)
- [Hummingbird Bioscience to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference](https://hummingbirdbioscience.com/hummingbird-bioscience-to-participate-in-the-morgan-stanley-20th-annual-global-healthcare-conference/)
- [Hummingbird Bioscience Announces Trial in Progress Poster Presentation at the European Society for Medical Oncology Congress 2022](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-trial-in-progress-poster-presentation-at-the-european-society-for-medical-oncology-congress-2022/)
- [Hummingbird Bioscience Chief Scientific Officer Jerome Boyd-Kirkup to Present at the 2nd Annual VISTA Virtual Symposium](https://hummingbirdbioscience.com/hummingbird-bioscience-chief-scientific-officer-jerome-boyd-kirkup-to-present-at-the-2nd-annual-vista-virtual-symposium/)
- [Hummingbird Bioscience Holds Opening Ceremony for Singapore Science Park Office and Research Facilities](https://hummingbirdbioscience.com/hummingbird-bioscience-holds-opening-ceremony-for-singapore-science-park-office-and-research-facilities/)
- [Hummingbird Bioscience to Attend the Credit Suisse 31st Annual Healthcare Conference](https://hummingbirdbioscience.com/hummingbird-bioscience-to-attend-the-credit-suisse-31st-annual-healthcare-conference/)
- [Hummingbird Bioscience Announces Two HMBD-002 Poster Presentations at the Society for Immunotherapy of Cancer 2022 Annual Meeting](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-two-hmbd-002-poster-presentations-at-the-society-for-immunotherapy-of-cancer-2022-annual-meeting/)
- [Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program](https://hummingbirdbioscience.com/hummingbird-bioscience-and-synaffix-enter-license-agreement-to-develop-a-next-generation-antibody-drug-conjugate-adc-program/) - Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and engineer antibodies against optimal yet elusive epitopes, thereby unlocking novel mechanisms of action, today announced that they entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation ADC program using Synaffix technology.
- [Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001](https://hummingbirdbioscience.com/hummingbird-bioscience-exercises-its-option-to-license-the-clinical-trial-results-from-cancer-research-uk-to-support-further-development-of-hmbd-001/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today announced that Hummingbird Bioscience has exercised its option to license in the first-in-human (FIH) clinical trial results of HMBD-001, a differentiated and potentially best-in-class HER3-targeting antibody.
- [Hummingbird Bioscience to Present Two Posters on HER3-Targeting Therapeutics at American Association for Cancer Research (AACR) Meeting 2023](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-two-posters-on-her3-targeting-therapeutics-at-aacr-2023/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) Meeting 2023 (April 14-19) in Orlando, Florida.
- [Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-preclinical-proof-of-concept-for-potentially-first-in-class-antibody-targeting-autoimmune-diseases/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at IMMUNOLOGY2023™. The company will present preclinical data for HMBD-011, an anti-VH4-34 antibody developed with Hummingbird Bioscience’s Rational Antibody Discovery platform. HMBD-011 is a potentially first-in-class anti-VH4-34 antibody developed for treatment of VH4-34+ antibody-driven pathogenesis in lupus and cold agglutinin disease.
- [Hummingbird Bioscience and Merck Enter Collaboration to Evaluate HMBD-001 In Squamous Non-Small Cell Lung Carcinoma](https://hummingbirdbioscience.com/hummingbird-bioscience-and-merck-enter-collaboration-to-evaluate-hmbd-001-in-squamous-non-small-cell-lung-carcinoma/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced it has entered into a clinical trial collaboration and supply agreement with Merck to evaluate HMBD-001 in combination with cetuximab in squamous non-small cell lung carcinoma
- [Hummingbird Bioscience Initiates HMBD-001 Phase IB Trials in Australia and Partners with Omico to Accelerate Clinical Development](https://hummingbirdbioscience.com/hummingbird-bioscience-initiates-hmbd-001-phase-ib-trials-in-australia-and-partners-with-omico-to-accelerate-clinical-development/) - Hummingbird Bioscience has initiated two clinical trials in Australia evaluating HMBD-001 in patients with squamous non-small cell lung cancer and patients with genetic aberrations in HER3 signaling. Hummingbird Bioscience has partnered with Omico to accelerate clinical development of HMBD-001, leveraging Omico’s PrOSPeCT initiative and network in Australia to recruit patients with gene signatures most likely to benefit from HMBD-001.
- [Hummingbird Bioscience Announces HMBD-002 Trials in Progress Poster at ASCO Annual Meeting 2023](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-hmbd-002-trials-in-progress-poster-at-asco-annual-meeting-2023/)
- [Hummingbird Bioscience to Present Poster on HMBD-001 Combination Strategy for Squamous Non-Small Cell Lung Cancer at World Conference on Lung Cancer 2023](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-poster-on-hmbd-001-combination-strategy-for-squamous-non-small-cell-lung-cancer-at-world-conference-on-lung-cancer-2023/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at the IASLC 2023 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (9-12 September 2023, Singapore). The poster will highlight the scientific rationale for combining anti-HER3 antibody HMBD-001 with EGFR inhibition and chemotherapy to improve treatment outcomes in squamous non-small cell lung cancer (sqNSCLC).
- [Hummingbird Bioscience Announces Positive Phase I Clinical Data for HMBD-001 Monotherapy Trial at the European Society for Medical Oncology Congress 2023](https://hummingbirdbioscience.com/hummingbird-bioscience-announces-positive-phase-i-clinical-data-for-hmbd-001-monotherapy-trial-at-the-european-society-for-medical-oncology-congress-2023/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced presentation of positive clinical data for the dose escalation part of the HMBD-001 Phase I/IIa trial (NCT05057013) at the European Society for Medical Oncology Congress 2023 (ESMO 2023). The trial is evaluating HMBD-001 as a monotherapy across various tumor types in the UK.
- [Hummingbird Bioscience Strengthens Leadership Team with Appointment of Angèle Maki as Chief Business Officer](https://hummingbirdbioscience.com/hummingbird-bioscience-strengthens-leadership-team-with-appointment-of-angele-maki-as-chief-business-officer/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the appointment of Angèle Maki, Ph.D., as Chief Business Officer, effective immediately.
- [Hummingbird Bioscience to Present Two Posters on Anti-HER3 and Anti-VISTA Antibody Therapeutics at American Association for Cancer Research (AACR) Meeting 2024](https://hummingbirdbioscience.com/hummingbird-bioscience-to-present-two-posters-on-anti-her3-and-anti-vista-antibody-therapeutics-at-american-association-for-cancer-research-aacr-meeting-2024/) - Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced two upcoming poster presentations at the American Association for Cancer Research (AACR) Meeting 2024 (April 5-10) in San Diego, California.
- [Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024](https://hummingbirdbioscience.com/hummingbird-bioscience-and-dartmouths-geisel-school-of-medicine-to-co-host-3rd-annual-virtual-vista-symposium-on-march-27-2024/) - Hummingbird Bioscience and Dartmouth’s Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
- [[Herald Interview] Singaporean antibody firm draws throngs of Korean investors](https://hummingbirdbioscience.com/herald-interview-singaporean-antibody-firm-draws-throngs-of-korean-investors-2/)
- [Hummingbird Bioscience Scientific Advisory Board member Prof. John Connolly appointed as Chief Scientific Officer at the Parker Institute for Cancer Immunotherapy](https://hummingbirdbioscience.com/hummingbird-bioscience-scientific-advisory-board-member-prof-john-connolly-appointed-as-chief-scientific-officer-at-the-parker-institute-for-cancer-immunotherapy/)
- [Scrip interview with Piers Ingram, CEO of Hummingbird Bioscience](https://hummingbirdbioscience.com/scrip-interview-with-piers-ingram-ceo-of-hummingbird-bioscience/)
- [Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy](https://hummingbirdbioscience.com/caris-life-sciences-and-hummingbird-bioscience-enter-into-collaboration-to-advance-clinical-development-of-anti-her3-therapy/)
- [[Herald Interview] Singaporean antibody firm draws throngs of Korean investors](https://hummingbirdbioscience.com/herald-interview-singaporean-antibody-firm-draws-throngs-of-korean-investors/)
- [Singapore biotech firm hopes for ‘widespread’ release of new Covid-19 treatment by early 2021](https://hummingbirdbioscience.com/singapore-biotech-firm-hopes-for-widespread-release-of-new-covid-19-treatment-by-early-2021/)
- [[BioWorld Interview] Hummingbird taps Tempus’ AI for clinical trial in rare NRG1 fusion patients](https://hummingbirdbioscience.com/bioworld-interview-hummingbird-taps-tempus-ai-for-clinical-trial-in-rare-nrg1-fusion-patients/)
- [New biotech facility Hummingbird Bioscience opens](https://hummingbirdbioscience.com/new-biotech-facility-hummingbird-bioscience-opens/)
- [王瑞杰出席“蜂鸟”生物医药科研设施开幕：引进全球人才有助我国打造科研绿洲](https://hummingbirdbioscience.com/ang-ruijie-attended-the-opening-of-the-hummingbird-biomedical-scientific-research-facility/)
- [Biomed start-up Hummingbird Bioscience opens new facility to boost its R&D work](https://hummingbirdbioscience.com/biomed-start-up-hummingbird-bioscience-opens-new-facility-to-boost-its-rd-work/)
- [HER3-addicted tumors: how biotechs are closing in](https://hummingbirdbioscience.com/her3-addicted-tumors-how-biotechs-are-closing-in/)
- [Eyeing clinical proof-of-concept for HER3 drug, Amgen-partnered biotech scores $125M for precision antibodies](https://hummingbirdbioscience.com/eyeing-clinical-proof-of-concept-for-her3-drug-amgen-partnered-biotech-scores-125m-for-precision-antibodies/)
- [Hummingbird CEO and Co-Founder Piers Ingram speaks to PharmaBoardroom in exclusive interview](https://hummingbirdbioscience.com/hummingbird-ceo-and-co-founder-piers-ingram-speaks-to-pharmaboardroom-in-exclusive-interview/)
- [[Asia Healthcare Podcast Interview] Our CEO and CO-Founder Piers Ingram discusses how systems biology and data science have advanced the understanding of disease, and how Hummingbird’s unique multidisciplinary approach unites the power of these two fields to create revolutionary therapies.](https://hummingbirdbioscience.com/asia-healthcare-podcast-interview-our-ceo-and-co-founder-piers-ingram-discusses-how-systems-biology-and-data-science-have-advanced-the-understanding-of-disease-and-how-hummingbirds-unique/)
- [[DealStreetAsia Interview] Hummingbird speaks to DealStreetAsia about the company’s overall drug development this year and its positive outlook on future investments.](https://hummingbirdbioscience.com/dealstreetasia-interview-hummingbird-speaks-to-dealstreetasia-about-the-companys-overall-drug-development-this-year-and-its-positive-outlook-on-future-investments/)
- [Hummingbird Bioscience has been recognized with the Most Promising Innovation title at Singapore’s SG:D Techblazer Awards 2020, the nation’s highest accolade for tech innovation.](https://hummingbirdbioscience.com/hummingbird-bioscience-has-been-recognized-with-the-most-promising-innovation-title-at-singapores-sgd-techblazer-awards-2020-the-nations-highest-accolade-for-tech-innovation/)
- [The Business Times lists Hummingbird Bioscience as one of the Top 10 Startups to watch in Singapore in 2021.](https://hummingbirdbioscience.com/the-business-times-lists-hummingbird-bioscience-as-one-of-the-top-10-startups-to-watch-in-singapore-in-2021/)

## Pages

- [Home](https://hummingbirdbioscience.com/) - Hummingbird Bioscience is leading a bold new way of engineering precision biotherapeutics that can define the future of precision medicine.
- [About Us](https://hummingbirdbioscience.com/about-us/) - We are a clinical-stage biotechnology company with a proprietary and differentiated Rational Antibody Discovery (RAD) platform, developing a broad pipeline of novel, precision therapeutics for the treatment of cancer and autoimmune disease.
- [Patients](https://hummingbirdbioscience.com/patients/) - Hummingbird Bioscience is dedicated to ensuring that patients receive the maximum benefit from our treatments. The company has dedicated resources over the years in understanding the underlying biology of different cancers and creating antibody therapeutics that will best suit patients.
- [Partnering](https://hummingbirdbioscience.com/partnering/) - Hummingbird Bioscience welcomes opportunities for collaboration. We have partnerships with global biopharma and research institutes to further our clinical therapies and extend the reach of our proprietary antibody-drug conjugate and antibody platforms.
- [Publications & Posters](https://hummingbirdbioscience.com/publications/) - Latest Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2017](https://hummingbirdbioscience.com/publications/publications-posters-2017/) - 2017 Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2018](https://hummingbirdbioscience.com/publications/publications-posters-2018/) - 2018 Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2019](https://hummingbirdbioscience.com/publications/publications-posters-2019/) - 2019 Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2020](https://hummingbirdbioscience.com/publications/publications-posters-2020/) - 2020 Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2021](https://hummingbirdbioscience.com/publications/publications-posters-2021/) - 2021 Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2022](https://hummingbirdbioscience.com/publications/publications-posters-2022/) - 2022 Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2023](https://hummingbirdbioscience.com/publications/publications-posters-2023/) - 2023 Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2024](https://hummingbirdbioscience.com/publications/publications-posters-2024/) - 2024 Publications and Posters from Hummingbird Bioscience.
- [Publications & Posters - 2025](https://hummingbirdbioscience.com/publications/publications-posters-2025/) - 2025 Publications and Posters from Hummingbird Bioscience.
- [News - 2025](https://hummingbirdbioscience.com/news/news-2025/) - 2025 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News - 2024](https://hummingbirdbioscience.com/news/news-2024/) - 2024 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News - 2023](https://hummingbirdbioscience.com/news/news-2023/) - 2023 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News - 2022](https://hummingbirdbioscience.com/news/news-2022/) - 2022 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News - 2021](https://hummingbirdbioscience.com/news/news-2021/) - 2021 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News - 2020](https://hummingbirdbioscience.com/news/news-2020/) - 2020 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News - 2019](https://hummingbirdbioscience.com/news/news-2019/) - 2019 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News - 2018](https://hummingbirdbioscience.com/news/news-2018/) - 2018 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News - 2017](https://hummingbirdbioscience.com/news/news-2017/) - 2017 News, Announcements, Press Releases from Hummingbird Bioscience.
- [News](https://hummingbirdbioscience.com/news/) - Latest News, Announcements, Press Releases from Hummingbird Bioscience.
- [HMBD-501](https://hummingbirdbioscience.com/hmbd-501/) - HMBD-501 represents a potentially best-in-class HER3-ADC combining Hummingbird Bioscience’s data-rich, systems biology approach to rational antibody discovery with state-of-the-art bioconjugation technologies.
- [Pipeline](https://hummingbirdbioscience.com/pipeline/) - Hummingbird Bioscience is developing a rich pipeline of differentiated assets.
- [HMBD-001](https://hummingbirdbioscience.com/hmbd-001/) - HMBD-001 is our flagship precision therapy program that targets HER3, a potent driver of tumor growth and resistance against cancer drugs.
- [ADC Platform](https://hummingbirdbioscience.com/adc-platform/) - Antibody-drug conjugates have the potential to become the backbone of future oncology therapy, however earlier generations of ADCs continue to face key challenges in safety and efficacy.
- [HMBD-002](https://hummingbirdbioscience.com/hmbd-002/) - HMBD-002 represents a unique first-in-class anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development.
- [Privacy Policy](https://hummingbirdbioscience.com/privacy-policy/) - Privacy Policy
- [Join Us](https://hummingbirdbioscience.com/careers/) - When you join Hummingbird Bioscience, you join a passionate team rising to some of the biggest challenges in science to engineer and develop next-generation therapies for a new world of precision medicine.
- [Antibody Platform](https://hummingbirdbioscience.com/antibody-platform/) - Hummingbird Bioscience’s Rational Antibody Discovery platform leverages data-rich, systems biology approaches to identify critical functional regions of a target protein, drive production of antibodies against these epitopes, and then isolate the antibodies that bind to them, thereby optimizing the therapeutic potential of a target.
- [Contact](https://hummingbirdbioscience.com/contact/) - If you would like to chat about potential opportunities, please contact us via these email addresses.
- [mAbPredictAI](https://hummingbirdbioscience.com/mabpredict-ai/) - mAbPredictAI mAbPredictAI is the AI-enabled module of the Rational Antibody Discovery platform that leverages data-rich, systems biology approaches to identify critical functional regions of a target protein. mAbPredict determines the disease-associated epitopes that mAbHits AbvantageTM will engineer an immune response towards. AI-Enabled Identification of Functional Epitopes To identify potentially valuable epitopes, mAbPredictAI will deploy all
- [mAbHits Abvantage™](https://hummingbirdbioscience.com/mabhits-abvantage/) - mAbHits AbvantageTM The mAbHits AbvantageTM module of the Rational Antibody Discovery platform is an immunoengineering system that manipulates the immune response to control the production of antibodies against defined optimal yet elusive epitopes on a disease-associated protein. AbvantageTM induces a specific and elevated immune response, generating affinity maturation of antibodies against optimal epitopes. Classical Approaches
- [Linker](https://hummingbirdbioscience.com/linker/) - Next-Generation Linker Technology Hummingbird Bioscience has developed a proprietary, differentiated linker technology that enables next-generation dual-payload conjugates. Our technology is capable of producing stable, developable conjugates across various formats. Targeting format agnostic – conjugation possible to antibodies, peptides, fragments and more Stable conjugates – designed for manufacturability, hydrophilicity, and non-immunogenicity Payload and DAR flexibility – applicable
- [TopDDRive™](https://hummingbirdbioscience.com/topddrive/) - TopDDRiveTM Despite initial efficacy, majority of patients develop resistance to topoisomerase 1 inhibitor (Topo1i) ADCs, and further lines of treatment are limited. The DNA damage repair pathway is a key driver of resistance to Topo1i ADCs, and blocking DNA damage response sensitizes cells to Topo1i. TopDDRiveTM is our dual-payload ADC approach for targeted delivery of
- [Science](https://hummingbirdbioscience.com/science/) - At Hummingbird Bioscience, we believe that our unique, multidisciplinary approach that combines systems biology with data science can overcome the challenges of classical methods of therapeutics discovery, and fundamentally transform the delivery of truly personalized medicines.
- [404](https://hummingbirdbioscience.com/404-2/) - Page not found.

## Categories

- [Publications & Posters](https://hummingbirdbioscience.com/category/publications-posters/)
- [News](https://hummingbirdbioscience.com/category/news/)
- [News - 2022](https://hummingbirdbioscience.com/category/news/news-2022/)
- [News – 2021](https://hummingbirdbioscience.com/category/news/news-2021/)
- [News – 2020](https://hummingbirdbioscience.com/category/news/news-2020/)
- [News – 2019](https://hummingbirdbioscience.com/category/news/news-2019/)
- [News – 2018](https://hummingbirdbioscience.com/category/news/news-2018/)
- [News – 2017](https://hummingbirdbioscience.com/category/news/news-2017/)
- [News - 2023](https://hummingbirdbioscience.com/category/news/news-2023/)
- [News – 2024](https://hummingbirdbioscience.com/category/news/news-2024/)
- [Publications](https://hummingbirdbioscience.com/category/publications-posters/publications/)
- [Posters](https://hummingbirdbioscience.com/category/publications-posters/posters/)
- [HMBD-001](https://hummingbirdbioscience.com/category/publications-posters/hmbd-001/)
- [HMBD-002](https://hummingbirdbioscience.com/category/publications-posters/hmbd-002/)
- [HMBD-501](https://hummingbirdbioscience.com/category/publications-posters/hmbd-501/)
- [HMBD-011](https://hummingbirdbioscience.com/category/publications-posters/hmbd-011/)
- [Posters - 2024](https://hummingbirdbioscience.com/category/publications-posters/posters/posters-2024/)
- [Posters - 2023](https://hummingbirdbioscience.com/category/publications-posters/posters/posters-2023/)
- [Posters - 2022](https://hummingbirdbioscience.com/category/publications-posters/posters/posters-2022/)
- [Posters - 2021](https://hummingbirdbioscience.com/category/publications-posters/posters/posters-2021/)
- [Publications - 2017](https://hummingbirdbioscience.com/category/publications-posters/publications/publications-2017/)
- [Publications – 2018](https://hummingbirdbioscience.com/category/publications-posters/publications/publications-2018/)
- [Publications – 2020](https://hummingbirdbioscience.com/category/publications-posters/publications/publications-2020/)
- [Publications – 2022](https://hummingbirdbioscience.com/category/publications-posters/publications/publications-2022/)
- [News - 2025](https://hummingbirdbioscience.com/category/news/news-2025/)
- [News - 2026](https://hummingbirdbioscience.com/category/news/news-2026/)

## Tags

- [RelatedNews-HMBD-001](https://hummingbirdbioscience.com/tag/relatednews-hmbd-001/)
- [RelatedNews-HMBD-002](https://hummingbirdbioscience.com/tag/relatednews-hmbd-002/)
- [PubPosts-HMBD-001](https://hummingbirdbioscience.com/tag/pubposts-hmbd-001/)
- [PubPosts-HMBD-002](https://hummingbirdbioscience.com/tag/pubposts-hmbd-002/)
- [PubPosts-HMBD-501](https://hummingbirdbioscience.com/tag/pubposts-hmbd-501/)
- [RelatedNews-HMBD-501](https://hummingbirdbioscience.com/tag/relatednews-hmbd-501/)
- [RelatedNews-HMBD-011](https://hummingbirdbioscience.com/tag/relatednews-hmbd-011/)
- [PubPosts-HMBD-011](https://hummingbirdbioscience.com/tag/pubposts-hmbd-011/)